Join Us On Facebook.
Follow us on Twitter.
Clearview News Wire
Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Lung cancer often recurs more than 5 years after resection
July 19, 2010
Last Updated: 2010-07-16 14:31:14 -0400 (Reuters Health)By Robert Saunders
NEW YORK (Reuters Health) - Patients with non-small-cell lung cancer (NSCLC) who don't have recurrence for 5 years after resection may not yet be free and clear. Some patients with certain tumor characteristics are at significant risk for a late recurrence, a Japanese team reports in the July issue of Chest.
Dr. Junji Yoshida and colleagues with the National Cancer Center Hospital East in Chiba analyzed data on 1358 patients who had complete resection of NSCLC with systematic lymph node dissection; 819 of them were free of recurrence for 5 years.
Subsequently, 87 of these patients (11%) had a late recurrence.
"Five years is not enough." Dr. Yoshida commented in an email to Reuters Health. "This is both for patient follow-up and for outcome evaluation. Five years has been the standard for both in lung cancer, but we showed there were a significant percentage of NSCLC patients developing recurrence beyond 5 years after surgical resection."
On multivariate analysis, the team found that factors disposing to recurrence more than 5 years after resection were intratumoral vascular invasion and nodal involvement.
Specifically, they report, "The 5-year recurrence-free probabilities from the point of 5 years after primary tumor resection were 81% for patients with intratumoral vascular invasion (p<0.001), and 89%, 84%, and 65% for patients with N0, N1, and N2 cancers, respectively (p<0.001)."
"Patients with vascular invasion positive tumors are at almost a 2-fold risk and those with nodal involvement tumors are at a 4-fold risk of a late recurrence," Dr. Yoshida stated.
Summing up, he said, "Similarly to colorectal cancer, we need to follow lung cancer patients beyond 5 years and to evaluate treatment outcome based on 10-year follow-up."
In their paper, Dr. Yoshida and his colleagues add, "This has implications for whether scheduled long-term follow-up beyond 5 years is warranted, or whether patients should simply be counseled on symptom recognition."
SOURCE: http://link.reuters.com/dyh97m
Chest 2010;138:145-150.
Tweet
Other Articles:
- February 3, 2012
- Senators urge Komen to reconsider funding decision
- February 1, 2012
- Eating fish tied to lower risk of colon polyps
- January 31, 2012
- Kids seek tans, use less sunscreen as they Age
- January 18, 2012
- FDA approves BTG's drug for cancer toxicity
- January 5, 2012
- Argentina's Fernandez undergoes cancer surgery
- December 20, 2011
- Vitamin D has mixed effects on cancer, broken bones
- December 13, 2011
- Memory issues after cancer may not be due to chemo
- December 8, 2011
- Quicker radiation therapy doubles mastectomy risk
- December 7, 2011
- Prostate cancer hormonal therapy cuts deaths: report
- November 17, 2011
- More fruit tied to lower risk of uterine fibroids
- November 15, 2011
- Brain scan study finds evidence of 'chemo brain'
- November 9, 2011
- No link between selenium, lower lung cancer risk
- November 8, 2011
- Singer Andy Williams reveals he has cancer
- November 7, 2011
- More evidence obesity tied to colon cancer
- November 4, 2011
- More evidence obesity tied to colon cancer